Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
SUMMARY
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Prostaglandin E2 receptor 4 (EP4) is a prostaglandin receptor encoded by the PTGER4 gene. The activity of the receptor is mediated by G proteins that stimulate adenylate cyclase. It has a relaxing effect on smooth muscle. It plays an important role in regulating renal hemodynamics, intestinal epithelial transport, adrenal aldosterone secretion, and uterine function.
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) pipeline Target constitutes close to 23 molecules. Out of which approximately 22 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 3, 1, 13 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively.
Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Musculoskeletal Disorders, Respiratory, Women's Health, Gastrointestinal, Genetic Disorders and Undisclosed which include indications Colorectal Cancer, Solid Tumor, Autoimmune Disorders, Gastric Cancer, Non-Small Cell Lung Cancer, Lung Cancer, Rectal Cancer, Triple-Negative Breast Cancer (TNBC), Unspecified Cancer, Breast Cancer, Chronic Obstructive Pulmonary Disease (COPD), Endometriosis, Esophageal Cancer, Gastroesophageal (GE) Junction Carcinomas, Head And Neck Cancer, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Liver Cancer, Metastatic Colorectal Cancer, Osteoarthritis, Pain, Pancreatic Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Allergies, Asthma, Bladder Cancer, Bone Defects, Cancer Pain, Cervical Cancer, Colon Cancer, Delirium, Endometrial Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2%li%Breast Cancer), Inflammation, Inflammatory Bowel Disease, Inflammatory Pain, Metastatic Pancreatic Cancer, Neuroinflammation, Osteoarthritis Pain, Osteogenesis Imperfecta, Osteoporosis, Pneumonia, Prostate Cancer, Rheumatoid Arthritis, Sarcomas, Squamous Non-Small Cell Lung Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Unspecified.
The latest report Prostaglandin E2 Receptor EP4 Subtype - Drugs In Development, 2022, outlays comprehensive information on the Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Prostaglandin E2 receptor 4 (EP4) is a prostaglandin receptor encoded by the PTGER4 gene. The activity of the receptor is mediated by G proteins that stimulate adenylate cyclase. It has a relaxing effect on smooth muscle. It plays an important role in regulating renal hemodynamics, intestinal epithelial transport, adrenal aldosterone secretion, and uterine function.
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) pipeline Target constitutes close to 23 molecules. Out of which approximately 22 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 3, 1, 13 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively.
Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Musculoskeletal Disorders, Respiratory, Women's Health, Gastrointestinal, Genetic Disorders and Undisclosed which include indications Colorectal Cancer, Solid Tumor, Autoimmune Disorders, Gastric Cancer, Non-Small Cell Lung Cancer, Lung Cancer, Rectal Cancer, Triple-Negative Breast Cancer (TNBC), Unspecified Cancer, Breast Cancer, Chronic Obstructive Pulmonary Disease (COPD), Endometriosis, Esophageal Cancer, Gastroesophageal (GE) Junction Carcinomas, Head And Neck Cancer, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Liver Cancer, Metastatic Colorectal Cancer, Osteoarthritis, Pain, Pancreatic Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Allergies, Asthma, Bladder Cancer, Bone Defects, Cancer Pain, Cervical Cancer, Colon Cancer, Delirium, Endometrial Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2%li%Breast Cancer), Inflammation, Inflammatory Bowel Disease, Inflammatory Pain, Metastatic Pancreatic Cancer, Neuroinflammation, Osteoarthritis Pain, Osteogenesis Imperfecta, Osteoporosis, Pneumonia, Prostate Cancer, Rheumatoid Arthritis, Sarcomas, Squamous Non-Small Cell Lung Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Unspecified.
The latest report Prostaglandin E2 Receptor EP4 Subtype - Drugs In Development, 2022, outlays comprehensive information on the Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)
- The report reviews Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Overview
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Companies Involved in Therapeutics Development
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Drug Profiles
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Dormant Products
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Discontinued Products
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Product Development Milestones
Featured News & Press Releases
Apr 27, 2022: Tempest announces poster presentations at the upcoming 2022 ASCO Annual Meeting
Apr 08, 2022: Tempest presents promising preclinical data on TPST-1495 at the 2022 AACR Annual Meeting
Nov 18, 2021: Tempest announces first patient dosed with TPST-1495 in Combination with Pembrolizumab
Nov 12, 2021: Tempest presents data supporting the dual mechanism of TPST-1495 as an optimal approach for targeting the prostaglandin pathway in cancer
Nov 08, 2021: Tempest Further bolsters patent portfolio with issuance of multiple patents for TPST-1495
Oct 01, 2021: Tempest announces presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Sep 08, 2021: Adlai Nortye announces first patient dosed in phase Ia clinical trial of AN0025 in combination with atezolizumab for advanced solid tumors
Aug 24, 2020: Adlai Nortye announces first patient dosed in phase 1b clinical trial of AN0025 (EP4 Antagonist) in combination with Merck's KEYTRUDA (pembrolizumab) for advanced solid tumors
Jan 30, 2020: Tempest Therapeutics announces FDA clearance of investigational new drug application for TPST-1495 and welcomes new investors
Sep 30, 2019: Adlai Nortye presents encouraging phase 1b study data of AN0025 at ESMO 2019
Sep 30, 2019: Adlai Nortye presents encouraging phase 1b study data of AN0025 (an Oral EP4 Antagonist) for locally advanced rectal cancer at ESMO 2019
May 07, 2019: Kyn Therapeutics strengthens leadership team with key appointments
Dec 20, 2018: Kyn Therapeutics and Merck begin Phase Ib/I trials of ARY-007
Jul 19, 2018: Investigational New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Is Approved in China
Apr 17, 2018: Japan Patent Office Granted AskAt a Cartilage Disease Use Patent of EP4 Antagonist
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Overview
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Companies Involved in Therapeutics Development
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Drug Profiles
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Dormant Products
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Discontinued Products
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Product Development Milestones
Featured News & Press Releases
Apr 27, 2022: Tempest announces poster presentations at the upcoming 2022 ASCO Annual Meeting
Apr 08, 2022: Tempest presents promising preclinical data on TPST-1495 at the 2022 AACR Annual Meeting
Nov 18, 2021: Tempest announces first patient dosed with TPST-1495 in Combination with Pembrolizumab
Nov 12, 2021: Tempest presents data supporting the dual mechanism of TPST-1495 as an optimal approach for targeting the prostaglandin pathway in cancer
Nov 08, 2021: Tempest Further bolsters patent portfolio with issuance of multiple patents for TPST-1495
Oct 01, 2021: Tempest announces presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Sep 08, 2021: Adlai Nortye announces first patient dosed in phase Ia clinical trial of AN0025 in combination with atezolizumab for advanced solid tumors
Aug 24, 2020: Adlai Nortye announces first patient dosed in phase 1b clinical trial of AN0025 (EP4 Antagonist) in combination with Merck's KEYTRUDA (pembrolizumab) for advanced solid tumors
Jan 30, 2020: Tempest Therapeutics announces FDA clearance of investigational new drug application for TPST-1495 and welcomes new investors
Sep 30, 2019: Adlai Nortye presents encouraging phase 1b study data of AN0025 at ESMO 2019
Sep 30, 2019: Adlai Nortye presents encouraging phase 1b study data of AN0025 (an Oral EP4 Antagonist) for locally advanced rectal cancer at ESMO 2019
May 07, 2019: Kyn Therapeutics strengthens leadership team with key appointments
Dec 20, 2018: Kyn Therapeutics and Merck begin Phase Ib/I trials of ARY-007
Jul 19, 2018: Investigational New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Is Approved in China
Apr 17, 2018: Japan Patent Office Granted AskAt a Cartilage Disease Use Patent of EP4 Antagonist
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Indications, 2022 (Contd..2)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Companies, 2022 (Contd..4)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by AskAt Inc, 2022
Pipeline by Domain Therapeutics SA, 2022
Pipeline by Draconis Pharma SL, 2022
Pipeline by Eisai Co Ltd, 2022
Pipeline by Exalys Therapeutics Inc, 2022
Pipeline by GSK plc, 2022
Pipeline by Gurus BioPharm Inc, 2022
Pipeline by Ionova Life Science Co Ltd, 2022
Pipeline by Kaken Pharmaceutical Co Ltd, 2022
Pipeline by Medibiofarma SL, 2022
Pipeline by Mesentech Inc, 2022
Pipeline by NB Health Laboratory Co Ltd, 2022
Pipeline by Ono Pharmaceutical Co Ltd, 2022
Pipeline by Oscotec Inc, 2022
Pipeline by RaQualia Pharma Inc, 2022
Pipeline by Rottapharm Biotech Srl, 2022
Pipeline by Shanghai Bioray Laboratory Inc, 2022
Pipeline by Sosei Group Corp, 2022
Pipeline by Tempest Therapeutics Inc, 2022
Pipeline by Teon Therapeutics Inc, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022
Discontinued Products, 2022 (Contd..1)
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Indications, 2022 (Contd..2)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Companies, 2022 (Contd..4)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by AskAt Inc, 2022
Pipeline by Domain Therapeutics SA, 2022
Pipeline by Draconis Pharma SL, 2022
Pipeline by Eisai Co Ltd, 2022
Pipeline by Exalys Therapeutics Inc, 2022
Pipeline by GSK plc, 2022
Pipeline by Gurus BioPharm Inc, 2022
Pipeline by Ionova Life Science Co Ltd, 2022
Pipeline by Kaken Pharmaceutical Co Ltd, 2022
Pipeline by Medibiofarma SL, 2022
Pipeline by Mesentech Inc, 2022
Pipeline by NB Health Laboratory Co Ltd, 2022
Pipeline by Ono Pharmaceutical Co Ltd, 2022
Pipeline by Oscotec Inc, 2022
Pipeline by RaQualia Pharma Inc, 2022
Pipeline by Rottapharm Biotech Srl, 2022
Pipeline by Shanghai Bioray Laboratory Inc, 2022
Pipeline by Sosei Group Corp, 2022
Pipeline by Tempest Therapeutics Inc, 2022
Pipeline by Teon Therapeutics Inc, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022
Discontinued Products, 2022 (Contd..1)
LIST OF FIGURES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
